Posted by Michael Wonder on 10 Nov 2022
BioLineRx announces US FDA acceptance of new drug application for Aphexda (motixafortide) in stem cell mobilisation
10 November 2022 - PDUFA target action date set for 9 September 2023.
BioLineRx today announced that the US FDA has accepted for review and filed the Company's new drug application for Aphexda (motixafortide) in stem cell mobilisation for autologous transplantation in multiple myeloma patients.
